Study of Procoagulation Markers in Stroke Patients "I-SPOT"


Phase N/A Results N/A

Eligibility Criteria

Inclusion Criteria

- Enrolled in SHINE study
- Ability to give Informed Consent (self or LAR)

Exclusion Criteria

- Current or planned use of full dose anticoagulation from baseline to the 48 hour sample collection
- Known moderate or severe hepatic insufficiency (as defined by INR>1.5 if known or history of variceal bleeding or hepatic encephalopathy)
- Prior or concurrent thrombotic or hypercoagulable condition (Antiphospholipid antibody syndrome; Antithrombin III, Protein C or S deficiencies; Congenital or Inherited Factor deficiencies; sickle cell disease)